03/20/2023
Alembic obtains FDA OK for generic Rexulti
Brexpiprazole tablets are indicated as an adjunctive therapy to antidepressants for the treatment of major depressive disorder and for the treatment of schizophrenia.
Alembic has received the Food and Drug Administration’s permission for brexpiprazole tablets in dosage strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.
Alembic's product is the generic of Otsuka Pharmaceutical’s Rexulti, which is indicated as an adjunctive therapy to antidepressants for the treatment of major depressive disorder and for the treatment of schizophrenia.
[Read more: Alembic rolls out generic Hygroton]
Brexpiprazole tablets have a market value of roughly $1.6 billion for the 12 months ended December 2022, according to IQVIA.
[Read more: Alembic intros generic Perforomist]